Evaluation of serum metallothionein-1, selenium, zinc, and copper in Ghanaian type 2 diabetes mellitus patients

International Journal of Diabetes in Developing Countries

Volumn 33, Issue 2, 2013, Pages 86-95

  Asare, George Awuku ^a   Osae, Shiloh ^b   Nortey, Ezekiel Nii Noye ^a   Yambire, Faisal King ^a   Amedonu, Elsie ^a   Doku, Derick ^a   Annan, Yvonne ^a  

^a UNIVERSITY OF GHANA   (Ghana)

^b Ghana Atomic Energy Commission   (Ghana)

Author keywords

Diabetes; Ghanaian; Oxidative stress; Trace elements

Indexed keywords

EID: 84880274712     PISSN: 09733930     EISSN: 19983832     Source Type: Journal    
DOI: 10.1007/s13410-013-0111-9     Document Type: Article

References (73)

1. Amoah AGB, Owusu KO, Adjei S. Diabetes in Ghana: a community prevalence study in greater Accra. Diabetes Res Clin Pract. 2002;56:197-205.
2. Struthers AD, Morris AD. Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet. 2002;359:1430-2.
3. Cooper GJ, Phillips AR, Choong SY, Leonard BL, Crossman DJ, Brunton DH, et al. Regeneration of the heart in diabetes by selective copper chelation. Diabetes. 2004;53:2501-8.
4. Ferns GA, Lamb DJ, Taylor A. The possible role of copper ions in atherogenesis: the blue Janus. Atherosclerosis. 1997;133:139-52.
5. Culotta VC, Gitlin JD. Disorders of copper transport. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 3105-26.
6. de Diego-Otero Y, Romero-Zerbo Y, el Bekay R, Decara J, Sanchez L, Rodriguez-de F, et al. Alpha-tocopherol protects against oxidative stress in the fragile X knockout mouse: an experimental therapeutic approach for the Fmr1 deficiency. Neuropsychopharmacology. 2009;34:1011-26.
7. Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell Prolif. 1991;24:203-14.
8. Lyons TJ. Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes? Diabet Med. 1991;8:411-9.
9. Percival M. Antioxidants. Clinical Nutrition Insights. 1998;31:1-4.
10. Jacob RA. The integrated antioxidant system. Nutr Res. 1995;15:755-66.
11. Vallee BL, Falchuk KH. The biochemical basis of zinc physiology. Phys Rev. 1993;73:79-117.
12. Zhang B, Georgiev O, Hagmann M, Günes C, Cramer M, Faller P, et al. Activity of metal-responsive transcription factor 1 by toxic heavy metals and H2O2 in vitro is modulated by metallothionein. Mol Cell Biol. 2003;23:8471-85.
13. Kumari MV, Hiramatsu M, Ebadi M. Free radical scavenging actions of metallothionein isoforms I and II. Free Radic Res. 1998;29:93-101.
14. Li X, Cai L, Feng W. Daibetes and metallothionein. Mini Rev Med Chem. 2007;7:761-8.
15. Reifen RM, Zlotkin S. Nutritional needs of the preterm infant. In: Tsang RC, Lucas A, Uauy R, Zlotkin S. Baltimore: Williams& Wilkins; 1993. pp 195-208
16. Castillo-Duran C, Cassorla F. Trace minerals in human growth and development. J Pediatr Endocrinol Metab. 1994;12(5 Suppl 2):589-601.
17. Walter Jr RM, Uriu-Hare JY, Olin KL, Oster MH, Anawalt BD, Critchfield JW, et al. Copper, zinc, manganese, and magnesium status and complications of diabetes mellitus. Diabetes Care. 1991;14:1050-6.
18. Fujimoto S. Studies on the relationships between blood trace metal concentrations and the clinical status of patients with cerebrovascular disease, gastric cancer and diabetes mellitus. Hokkaido Igaku Zasshi. 1987;62:913-32.
19. Smith AM, Chan GM, Moyer-Mileur LJ, Johnson CE, Gardner BR. Selenium status of preterm infants fed human milk, preterm formula or selenium-supplemented preterm formula. J Pediatr. 1991;119:429-33.
20. Shenkin A, Baines M, Fell GS, Lyon TDG. Vitamins and Trace Elements. In: Burtis CA, Ashwood ER and Bruns DE, eds. Tietz textbook of clinical chemistry and molecular diagnostics. 4th edition. St.Louis, Missouri; 2006. 1126-28.
21. Shenkin A, Baines M, Fell GS, Lyon TDG. Vitamins and Trace Elements. In: Burtis CA, Ashwood ER and Bruns DE, eds. Tietz textbook of clinical chemistry and molecular diagnostics. 4th edition. St.Louis, Missouri; 2006. 1133.
22. Burk RF, Hill KE, Motley AK. Selenoprotein metabolism and function: evidence for more than one function for Selenoprotein P. J Nutr. 2003;133:S1517-20.
23. Chesters JK. Zinc. In: O'Dell BL, Sunde RA, editors. Handbook of nutritionally essential mineral elements. New York: Marcel Dekker; 1997. p. 185-230.
24. Wood RJ. Assessment of marginal zinc status in humans. J Nutr. 2000;130:1350-4.
25. Kazi TG, Afridi HI, Kazi N, Jamali MK, Arain MB, Jalbani N, et al. Copper, chromium, manganese, iron, nickel, and zinc levels in biological samples of diabetes mellitus patients. Biol Trace Elem Res. 2008;122:1-18.
26. Błazewicz A, Orlicz-Szczesna G, Prystupa A, Szczesny P. Use of ion chromatography for the determination of selected metals in blood serum of patients with type 2 diabetes. J Trace Elem Med Biol. 2010;24:14-9.
27. Serdar MA, Bakir F, Hasimi A, Celik T, Akin O, Kenar L, et al. Trace and toxic element patterns in nonsmoker patients with noninsulin-dependent diabetes mellitus, impaired glucose tolerance, and fasting glucose. Int J Diab Dev Ctries. 2009;29:35-40.
28. Cai L, Wang J, Li Y, Sun X, Wang L, Zhou Z, et al. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes. 2005;54:1829-37.
29. Cooper GJS, Young AA, Gamble GD, Cooper GJ, Young AA, Gamble GD, et al. A copper(II)- selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study. Diabetologia. 2009;52:715-22.
30. Zheng Y, Li XK, Wang Y, Cai L. The role of zinc, copper and iron in the pathogenesis of diabetes and diabetic complications: therapeutic effects by chelators. Haemoglobin. 2008;32:135-45.
31. Viktorínová A, Toserová E, Krizko M, Duracková Z. Altered metabolism of copper, zinc, and magnesium is associated with increased levels of glycated hemoglobin in patients with diabetes mellitus. Metabolism. 2009;58:1477-82.
32. Basaki M, Saeb M, Nazifi S, Shamsaei HA. Zinc, copper, iron, and chromium concentrations in young patients with type 2 diabetes mellitus. Biol Trace Elem Res. 2012;148:161-4.
33. Yu YP, Lei P, Hu J, Wu WH, Zhao YF, Li YM. Copper-induced cytotoxicity: reactive oxygen species or islet amyloid polypeptide oligomer formation. Chem Commun (Camb). 2010;46:6909-11.
34. Kang YJ. Copper and homocysteine in cardiovascular diseases. Pharmacology & Therapeutics. 2011;129:321-31.
35. Ahmed MU, Thorpe SR, Baynes JW. Identification of N-(carboxymethyl) lysine as a degradation product of fructose lysine in glycated protein. J Biol Chem. 1996;261:4889-94.
36. Qian M, Liu M, Eaton JW. Transition metals bind to glycated proteins forming redox active "glycochelates": implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Commun. 1998;250:385-9.
37. Mandinov L, Mandinova A, Kyurkchiev S, Kyurkchiev D, Kehayov I, Kolev V, et al. Copper chelation represses the vascular response to injury. Proc Natl Acad Sci USA. 2003;100:6700-5.
38. Flores CR, Puga MP, Wrobel K, Garay Sevilla ME, Wrobel K. Trace elements status in diabetes mellitus type 2: Possible role of the interaction between molybdenum and copper in the progress of typical complications. Diabetes Res Clin Pract. 2011;91:333-41.
39. Ohly P, Dohle C, Abel J, Seissler J, Gleichmann H. Zinc sulphate induces metallothionein in pancreatic islets of mice and protects against diabetesinduced by multiple low doses of streptozotocin. Diabetologia. 2000;43:1020-30.
40. Wang J, Song Y, Elsherif L, Song Z, Zhou G, Prabhu SD, et al. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation. 2006;113:544-54.
41. Isbir T, Tamer A, Taylor, Isbir M. Zinc, copper and magnesium status in insulin dependent diabetes. Diab Res. 1994;26:41-5.
42. Roth HP, Kirchgessner M. Zinc and insulin metabolism. Biol Trace Elem Res. 1981;3:13-32.
43. Cai L, Cherian MG. Zinc-metallothionein protects from DNA damage induced by radiation better than glutathione and copper- or cadmium-metallothioneins. Toxicol Lett. 2003;136:193-8.
44. Masood N, Baloch GH, Ghori RA, Memon IA, Memon MA, Memon MS. Serum zinc and magnesium in type-2 diabetic patients. J Coll Physicians Surg Pak. 2009;19:483-6.
45. Al-Maroof RA, Al-Sharbatti SS. Serum zinc levels in diabetic patients and effect of zinc supplementation on glycemic control of type 2 diabetics. Saudi Med J. 2006;3:344-50.
46. Ekin S, Mert N, Gunduz H, Meral I. Serum sialic acid levels and selected mineral status in patients with type 2 diabetes mellitus. Biol Trace Elem Res. 2003;94:193-201.
47. Craft NE, Failla ML. Zinc, iron, and copper absorption in the streptozotocin-diabetic rat. Am J Physiol. 1983;244:E122-8.
48. Escobar O, Sandoval M, Vargas A, Hempe JM. Role of metallothionein and cysteine-rich intestinal protein in the regulation of zinc absorption by diabetic rats. Pediatr Res. 1995;37:321-7.
49. Dodson G, Steiner D. The role of assembly in insulin's biosynthesis. Curr Opin Struct Biol. 1998;8:189-94.
50. Rutter GA. Think zinc. New roles for zinc in the control of insulin secretion. Islets. 2010;2:49-50.
51. Chausmer AB. Zinc, insulin and diabetes. J Am Coll Nutr. 1998;17:109-15.
52. Sheline CT, Behrens MM, Choi DW. Zinc-induced cortical neuronal death: contribution of energy failure attributable to loss of NAD(+) and inhibition of glycolysis. J Neurosci. 2000;20:3139-46.
53. Ohly P, Wang Z, Abel J, Gleichmann H. Zinc sulphate induced metallothionein in pancreatic islets and protected against the diabetogenic toxin streptozotocin. Talanta. 1998;46:355-9.
54. Nube M, Voortman RL. Simultaneously addressing micronutrient deficiencies in soils, crops, animal and human nutrition: opportunities for higher yield and better health. Amsterdam: Centre for World Food Studies, SOW-VU, De Boelelaan; 2006.
55. Chimienti F, Devergnas S, Favier A, Seve M. Identification and cloning of a betacell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. Diabetes. 2004;53:2330-7.
56. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science. 2007;316:1336-41.
57. Cauchi S, Meyre D, Durand E, Proença C, Marre M, Hadjadj S, et al. Post genome-wide association studies of novel genes associated with type 2 diabetes show gene-gene interaction and high predictive value. PLoS One. 2008;3:e2031.
58. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A. 2007;104:17040-5.
59. Jansen J, Rosenkranz E, Overbeck S, Warmuth S, Mocchegiani E, Giacconi R, et al. Disturbed zinc homeostasis in diabetic patients by in vitro and in vivo analysis of insulinomimetic activity of zinc. J Nutr Biochem. 2012;23:1458-66.
60. Quilliot D, Dousset B, Guerci B, Dubois F, Drouin P, Ziegler O. Evidence that diabetes mellitus favors impaired metabolism of zinc, copper, and selenium in chronic pancreatitis. Pancreas. 2001;22:299-306.
61. Bleys J, Navas-Acien A, Guallar E. Selenium and diabetes: more bad news for supplements. Ann Intern Med. 2007;147:271-2.
62. Hughes K, Choo M, Kuperan P, Ong CN, Aw TC. Cardiovascular risk factors in non-insulin-dependent diabetics compared to non-diabetic controls: a population- based survey among Asians in Singapore. Atherosclerosis. 1998;136:25-31.
63. Kornhauser C, Garcia-Ramirez JR, Wrobel K, Pérez-Luque EL, Garay-Sevilla ME, Wrobel K. Serum selenium and glutathione peroxidase concentrations in type 2 diabetes mellitus patients. Prim Care Diabetes. 2008;2:81-5.
64. Mueller AS, Pallauf J. Compendium of the antidiabetic effects of supranutritional selenate doses. In vivo and in vitro investigations with type II diabetic db/db mice. J Nutr Biochem. 2006;17:548-60.
65. Labunskyy VM, Lee BC, Handy DE, Loscalzo J, Hatfield DL, Gladyshev VN. Both maximal expression of selenoproteins and selenoprotein deficiency Can promote development of type 2 diabetes-like phenotype in mice. Antioxid Redox Signal. 2011;14:2327-36.
66. Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal. 2007;9:775-806.
67. Burk RF. Selenium, an antioxidant nutrient. Nutr Clin Care. 2002;5:75-9.
68. Stranges S, Sieri S, Vinceti M, Grioni S, Guallar E, Laclaustra M, et al. A prospective study of dietary selenium intake and risk of type 2 diabetes. BMC Public Health. 2010;10:564.
69. Zeng J, Zhou J, Huang K. Effect of selenium on pancreatic proinflammatory cytokines in streptozotocin-induced diabetic mice. J Nutr Biochem. 2009;20:530-6.
70. Fridlyand LE, Philipson LH. Oxidative reactive species in cell injury: mechanisms in diabetes mellitus and therapeutic approaches. Ann N Y Acad Sci. 2005;1066:136-51.
71. Drake EN. Cancer chemoprevention: selenium as a prooxidant, not an antioxidant. Med Hypotheses. 2006;67:318-22.
72. Sotiropoulos A, Papadodima AS, Papazafiropoulou AK, Loannidis A, Kokkinari A, Apostolou O, Spiliopoulou CA and Athanaselis S. Serum selenium levels do not differ in type 2 diabetic subjects with and without coronary artery disease. BMC Res Notes 2011;4:270.
73. Park K, Rimm EB, Siscovick DS, Spiegelman D, Manson JE, Morris JS, Hu FB, Mozaffarian D. Toenail Selenium and Incidence of Type 2 Diabetes Mellitus in U.S. Men and Women Diabetes Care Publish Ahead of Print, published online May 22, 2012. Diabetes Care. http://care.diabetesjournals.org/content/early/2012/05/ 20/dc11-2136.full.pdf (Accessed, July 2012)